Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is Galafold, an oral precision medicine for people living with Fabry disease who have amenable GLA variants. The lead biologics program in the Amicus Therapeutics pipeline is AT-GAA, an investigational therapy for Pompe disease. Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. Source
No articles found.
Predictive Oncology is a clinical and translational data pipeline and AI-driven pl...
Predictive Oncology is a clinical and translati...
BelleIQ operates ALLIES, an online marketplace selling health & wellness products ...
BelleIQ operates ALLIES, an online marketplace ...
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing thera...
At Catabasis Pharmaceuticals, our mission is to...
Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet...
Theratechnologies (TSX: TH) is a specialty phar...
Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel pr...
Novavax, Inc. is a clinical-stage vaccine compa...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel ...
Ultragenyx is a biopharmaceutical company commi...
Join the National Investor Network and get the latest information with your interests in mind.